PaxVax, a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases, today announced that the company has entered into a marketing and distribution agreement with Seqirus. Under the terms of this agreement, PaxVax will market, sell and distribute two of Seqirus’ influenza vaccine products in Switzerland, Agrippal® (surface antigen, inactivated) and Fluad™ (influenza vaccine, adjuvanted).
“PaxVax has deep expertise in the vaccine industry and has built a substantial global marketing, sales and distribution network that enables us to support vaccine makers serving major markets in North America and Europe,” said Nima Farzan, President and CEO of PaxVax. “We are pleased to partner with Seqirus, which is the second largest influenza vaccine manufacturer in the world, to ensure the availability of these important vaccines. With the addition of Agrippal and Fluad, PaxVax is building a robust portfolio of vaccines for the Swiss market that includes our own typhoid vaccine, Vivotif.”
Agrippal is an inactivated trivalent influenza virus vaccine indicated for adults and children older than 6 months. Fluad is an adjuvanted trivalent inactivated influenza vaccine indicated for adults 65 years and older.
PaxVax has established legal entities and commercial infrastructure to support its products in the United States, Italy, Portugal, Spain, Switzerland and the United Kingdom. In addition to its partnership with Seqirus, the company also markets and distributes Valneva’s travel vaccines in Italy, Spain and Portugal.
PaxVax develops, manufactures and commercializes innovative specialty vaccines against infectious diseases for traditionally overlooked markets such as travel. PaxVax has licensed vaccines for typhoid fever (Vivotif) and cholera (Vaxchora), and vaccines at various stages of research and clinical development including for adenovirus, anthrax, hepatitis A, HIV, and zika. As part of its social mission, PaxVax is also working to make its vaccines available to broader populations most affected by these diseases. PaxVax is headquartered in Redwood City, California and maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California and Bern, Switzerland and other operations in Bermuda and Europe. More information is available at www.PaxVax.com.
Colin Sanford, 415-870-9188
Source : businesswire.com